Within the next five to ten years, about 35% of today's biologics will be manufactured using process intensification methods, according to a MilliporeSigma market analysis. By that time, the facilities will be smaller but capable of processing higher volumes and multiple molecules. The key to this advancement will be single-use technologies that enable reductions in facility size, cycle times and environmental impact. These benefits, in turn, reduce capital investment, operational costs and build time, which will be trimmed from roughly five years to as little as 18 months.
This evolution will require culture change in the biopharmaceutical world, and everyone from manufacturers and vendors to regulators will need to be involved. If biomanufacturers are to remain competitive, they should collaborate with vendors and regulators to become early adopters and efficient users.